Graviton Bioscience公司正式对外披露，其针对弗里德赖希共济失调（Friedreich's Ataxia）所研发的新型药物GV101，已成功获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。这一里程碑式的进展，标志着该候选药物正式迈入人体临床试验阶段，为这一罕见神经系统疾病的治疗领域带来新的希望。
Graviton Bioscience公司正式对外披露，其针对弗里德赖希共济失调（Friedreich's Ataxia）所研发的新型药物GV101，已成功获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。这一里程碑式的进展，标志着该候选药物正式迈入人体临床试验阶段，为这一罕见神经系统疾病的治疗领域带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.